Convalescent plasma therapy for the treatment of COVID-19

Health Technology Wales
Record ID 32018002670
Authors' objectives: The report aims to identify and summarise evidence that addresses the following question: what is the clinical effectiveness of convalescent plasma therapy for people with COVID-19?
Authors' results and conclusions: Evidence suggests that convalescent plasma therapy does not provide benefits to people with COVID-19. There may be some benefits if the intervention is used in the early stages of symptoms developing, but these benefits are uncertain and likely to be negated by vaccination.
Authors' methods: The Evidence Appraisal Report is based on a literature search (strategy available on request) for published clinical and economic evidence on the health technology of interest. It is not a full systematic review but aims to identify the best available evidence on the health technology of interest. Researchers critically evaluate and synthesise this evidence. We include the following clinical evidence in order of priority: systematic reviews; randomised trials; non-randomised trials. We only include evidence for “lower priority” evidence where outcomes are not reported by a “higher priority” source. We also search for economic evaluations or original research that can form the basis of an assessment of costs/cost comparison.
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Wales, United Kingdom
MeSH Terms
  • Blood Component Transfusion
  • Coronavirus Infections
  • COVID-19
  • SARS-CoV-2
  • Immunization, Passive
  • Plasma
  • COVID-19
  • Convalescent plasma
  • COVID-19 serotherapy
Organisation Name: Health Technology Wales
Contact Address: Floor 3, 2 Capital Quarter, Tyndall Street, Cardiff, CF10 4BZ
Contact Name: Susan Myles, PhD
Contact Email:
Copyright: Health Technology Wales
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.